" /> Glioblastoma Multiforme Multipeptide Vaccine IMA950 - CISMeF





Preferred Label : Glioblastoma Multiforme Multipeptide Vaccine IMA950;

NCIt definition : A cancer vaccine comprised of 11 peptides associated with glioblastoma multiforme (GBM), with potential immunomodulating and antineoplastic activities. Vaccination with glioblastoma multiforme multi-antigen vaccine IMA950 stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response as well as a T-helper (Th) immune response against tumor cells expressing these peptides, potentially resulting in decreased tumor growth of GBM. Peptides in IMA950 consist of the following: brevican (BCAN); chondroitin sulfate proteoglycan 4 (CSPG4); fatty acid binding protein 7, brain (FABP7); insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3); neuroligin 4, X-linked (NLGN4X); neuronal cell adhesion molecule (NRCAM); protein tyrosine phosphatase, receptor-type, Z polypeptide 1 (PTPRZ1); tenascin C (TNC); Met proto-oncogene (MET); baculoviral IAP repeat-containing 5 (BIRC5); and hepatitis B virus core antigen.;

Molecule name : IMA950;

NCI Metathesaurus CUI : CL426024;

Details


Keyword's position in hierarchy(ies) : arborescence

You can consult :


Nous contacter.
09/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.